Towards a condensed screening platform for aggregation profiling
Lead Participant:
MALVERN INSTRUMENTS LIMITED
Abstract
Biotherapeutic drugs are an increasingly important class of new medicines and their effective action in the
therapeutic treatment of disease has attracted interest from both academic and industry sectors. Despite the
overwhelming benefits to patients, the availability of these drugs at point-of-care is inextricably linked to their
affordability. Currently, the costs associated with the development and production of safe and effective
biotherapeutic drugs are extremely high, and such costs must ultimately be passed on in the final drug product.
One of the major risk areas in drug development is the occurrence of bundles of drug molecules known as
aggregates, which can result in unwanted side-effects in patients or in a reduction of therapeutic effectiveness.
This project brings together biopharmaceutical companies, academic research leaders and developers of
scientific instruments in order to produce novel sensors that can improve the detection of drug aggregates
throughout the drug development process. With this novel analytical technology, we aim to attenuate the risks
associated with aggregation to ensure the delivery of safe and cost-effective drugs in the future.
therapeutic treatment of disease has attracted interest from both academic and industry sectors. Despite the
overwhelming benefits to patients, the availability of these drugs at point-of-care is inextricably linked to their
affordability. Currently, the costs associated with the development and production of safe and effective
biotherapeutic drugs are extremely high, and such costs must ultimately be passed on in the final drug product.
One of the major risk areas in drug development is the occurrence of bundles of drug molecules known as
aggregates, which can result in unwanted side-effects in patients or in a reduction of therapeutic effectiveness.
This project brings together biopharmaceutical companies, academic research leaders and developers of
scientific instruments in order to produce novel sensors that can improve the detection of drug aggregates
throughout the drug development process. With this novel analytical technology, we aim to attenuate the risks
associated with aggregation to ensure the delivery of safe and cost-effective drugs in the future.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
MALVERN INSTRUMENTS LIMITED | £427,159 | £ 213,579 |
  | ||
Participant |
||
PARAYTEC LIMITED | £332,622 | £ 232,835 |
CENTRE FOR PROCESS INNOVATION LIMITED | £105,470 | £ 105,470 |
UNIVERSITY OF CENTRAL LANCASHIRE | £46,465 | £ 46,465 |
MALVERN PANALYTICAL LIMITED | ||
CPI INNOVATION SERVICES LIMITED | ||
INNOVATE UK |
People |
ORCID iD |